Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Velcade bortezomib: Interim Phase III data

Interim results from the first 256 patients in an Italian Phase III trial showed that induction therapy with Velcade plus thalidomide

Read the full 214 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE